Potential value of anoikis transcriptional signatures in predicting prognosis and immune microenvironment in hepatocellular carcinoma.
1/5 보강
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.8%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
Resistance to anoikis, a crucial factor in cancer cell survival, drives the development and progression of numerous malignancies.
APA
Cheng FR, Song WY, et al. (2025). Potential value of anoikis transcriptional signatures in predicting prognosis and immune microenvironment in hepatocellular carcinoma.. Yi chuan = Hereditas, 47(7), 768-785. https://doi.org/10.16288/j.yczz.25-007
MLA
Cheng FR, et al.. "Potential value of anoikis transcriptional signatures in predicting prognosis and immune microenvironment in hepatocellular carcinoma.." Yi chuan = Hereditas, vol. 47, no. 7, 2025, pp. 768-785.
PMID
40675763 ↗
Abstract 한글 요약
Resistance to anoikis, a crucial factor in cancer cell survival, drives the development and progression of numerous malignancies. Hepatocellular carcinoma (HCC) is a malignant liver tumor characterized by high rates of recurrence and metastasis. However, the role of anoikis in HCC remains poorly understood. In this study, we identify 74 anoikis-related genes (ARGs) differentially expressed in HCC using the transcriptional data from The Cancer Genome Atlas (TCGA). Then, we develop a prognostic model incorporating 9 of these genes through LASSO-Cox regression analysis, and confirm the model's independent prognostic significance for overall survival in HCC patients by using multivariable Cox proportional hazards analysis. Furthermore, we observe significant enrichment of activated proliferation-related pathways, increased infiltration of immunosuppressive cells and resistance to anti-PD-L1 therapy in the high-risk group defined by this model. These findings suggest that the ARG model may serve as a novel prognostic indicator for HCC patients and underscore the critical role of anoikis in HCC progression.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.